Valuation: Interpace Biosciences, Inc.

Market Cap 35.58M 31.37M 29.67M 26.89M 50.48M 3.41B 50.93M 355M 137M 1.74B 134M 131M 5.59B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 34.26M 30.21M 28.57M 25.9M 48.61M 3.29B 49.04M 342M 132M 1.68B 129M 126M 5.39B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day+0.16%
1 week-0.47%
Current month-15.19%
1 month-15.73%
3 months-22.18%
6 months-23.57%
Current year+4.37%
1 week 6.01
Extreme 6.01
6.42
1 month 5.97
Extreme 5.9732
7.59
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
50.25
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 2020-11-30
Director of Finance/CFO 34 2023-04-20
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 2016-06-20
Director/Board Member 73 2015-12-31
Director/Board Member 64 2020-01-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 Free

Director

69,252 0.2501%
8/20/26 Exercice

Chief Financial Officer

1,385,045 5.0015%
8/20/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
+0.16%-0.47%+44.58%+42.67% 35.58M
+0.67%+11.84%+154.35%+814.65% 59.35B
-0.25%-3.79%+10.05%+51.93% 25.11B
-1.42%-3.75%-11.39%-37.03% 6.59B
-1.62%-2.70%-6.85%+146.38% 5.65B
+0.43%+1.56%+22.11%+61.95% 3.38B
-11.80%-22.53%-35.34%+2,103.20% 2.56B
-2.85%-3.45%+136.32%+49.80% 2.48B
+17.93%-0.36%+36.49%+45.41% 2.23B
-2.62%-1.77%-3.12%-54.70% 1.97B
Average -0.13%-0.84%+34.72%+322.43% 10.94B
Weighted average by Cap. +0.13%+3.17%+88.68%+511.65%

Financials

2024 2025
Net sales 46.93M 41.38M 39.14M 35.47M 66.58M 4.5B 67.17M 468M 181M 2.3B 176M 172M 7.38B 38.73M 34.15M 32.3M 29.28M 54.95M 3.72B 55.44M 386M 149M 1.9B 145M 142M 6.09B
Net income 6.7M 5.91M 5.59M 5.07M 9.51M 643M 9.59M 66.85M 25.78M 328M 25.16M 24.62M 1.05B 24.58M 21.67M 20.5M 18.58M 34.87M 2.36B 35.18M 245M 94.54M 1.2B 92.27M 90.26M 3.86B
Net Debt 4.4M 3.88M 3.67M 3.32M 6.24M 422M 6.29M 43.84M 16.91M 215M 16.5M 16.14M 691M -1.32M -1.17M -1.1M -999K -1.88M -127M -1.89M -13.19M -5.09M -64.77M -4.96M -4.86M -208M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
26-09-28 $6.420 +0.16% 313
26-09-25 $6.410 -0.93% 4,734

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXG Stock